{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:32:51Z","timestamp":1775835171023,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2020YFC2008306"],"award-info":[{"award-number":["2020YFC2008306"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jpba.2022.115017","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T23:04:49Z","timestamp":1661295889000},"page":"115017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Simultaneous determination of plasma lamotrigine, lamotrigine N2-glucuronide and lamotrigine N2-oxide by UHPLC-MS\/MS in epileptic patients"],"prefix":"10.1016","volume":"220","author":[{"given":"Hua","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shenghui","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.jpba.2022.115017_bib1","first-page":"S87","article-title":"Lamotrigine","volume":"36","author":"Messenheimer","year":"1995","journal-title":"EPILEPSIA"},{"key":"10.1016\/j.jpba.2022.115017_bib2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/npr2.12056","article-title":"Efficacy and safety of lithium and lamotrigine for the maintenance treatment of clinically stable patients with bipolar disorder: a systematic review and meta-analysis of double-blind, randomized, placebo-controlled trials with an enrichment design","volume":"39","author":"Oya","year":"2019","journal-title":"Neuropsychopharmacol. Rep."},{"key":"10.1016\/j.jpba.2022.115017_bib3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/pds.1690","article-title":"Trends and changes in the clinical use of lamotrigine","volume":"18","author":"Reimers","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"Suppl. 1","key":"10.1016\/j.jpba.2022.115017_bib4","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1177\/0883073897012001041","article-title":"Lamotrigine: pharmacokinetics","volume":"12","author":"Garnett","year":"1997","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.jpba.2022.115017_bib5","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/dmd.106.009340","article-title":"In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction","volume":"34","author":"Rowland","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.jpba.2022.115017_bib6","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/tx0000825","article-title":"Metabolism of lamotrigine to a reactive arene oxide intermediate","volume":"13","author":"Maggs","year":"2000","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.jpba.2022.115017_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1365-2125.1997.tb00133.x","article-title":"Comparison of the pharmacokinetics of lamotrigine in patients with chronic renal failure and healthy volunteers","volume":"43","author":"Wootton","year":"1997","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.jpba.2022.115017_bib8","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1248\/bpb.35.487","article-title":"Influence of concomitant antiepileptic drugs on plasma lamotrigine concentration in adult Japanese epilepsy patients","volume":"35","author":"Yamamoto","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.jpba.2022.115017_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.seizure.2020.07.014","article-title":"Sources of lamotrigine pharmacokinetic variability: a systematic review of population pharmacokinetic analyses","volume":"82","author":"Methaneethorn","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.jpba.2022.115017_bib10","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.eplepsyres.2011.02.002","article-title":"Lamotrigine and its N2-glucuronide during pregnancy: the significance of renal clearance and estradiol","volume":"94","author":"Reimers","year":"2011","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.jpba.2022.115017_bib11","unstructured":"FDALabel(2021\u201303-31)-LAMICTAL(Lamotrigine Tablets)(GlaxoSmithKline). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020241s064,020764s057,022251s028lbl.pdf."},{"key":"10.1016\/j.jpba.2022.115017_bib12","doi-asserted-by":"crossref","first-page":"5371854","DOI":"10.1155\/2018\/5371854","article-title":"Lamotrigine-valproic acid interaction leading to stevens-johnson syndrome","volume":"2018","author":"Vazquez","year":"2018","journal-title":"Case Rep. Med."},{"key":"10.1016\/j.jpba.2022.115017_bib13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0731-7085(90)80104-W","article-title":"Validation of a radioimmunoassay for the determination of human plasma concentrations of lamotrigine","volume":"8","author":"Biddlecombe","year":"1990","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2022.115017_bib14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00007691-200010000-00019","article-title":"Optimized procedure for lamotrigine analysis in serum by high-performance liquid chromatography without interferences from other frequently coadministered anticonvulsants","volume":"22","author":"Torra","year":"2000","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2022.115017_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jchromb.2005.09.009","article-title":"Simultaneous liquid chromatographic determination of lamotrigine, oxcarbazepine monohydroxy derivative and felbamate in plasma of patients with epilepsy","volume":"828","author":"Contin","year":"2005","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2022.115017_bib16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jchromb.2007.04.006","article-title":"Development of a simple column-switching high-performance liquid chromatography (HPLC) method for rapid and simultaneous routine serum monitoring of lamotrigine, oxcarbazepine and 10-monohydroxycarbazepine (MHD)","volume":"854","author":"Greiner","year":"2007","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2022.115017_bib17","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0021-9673(02)01257-8","article-title":"Therapeutic drug monitoring of lamotrigine using capillary electrophoresis. Evaluation of assay performance and quality assurance over a 4-year period in the routine arena","volume":"979","author":"Theurillat","year":"2002","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2022.115017_bib18","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1093\/jat\/bkaa095","article-title":"LC-MS-MS method for the quantitation of antiepileptic drugs in urine","volume":"44","author":"Feng","year":"2020","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.jpba.2022.115017_bib19","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1039\/D1AY01372F","article-title":"A LC-MS(3) strategy to determine lamotrigine by Q-Q-trap tandem mass spectrometry coupled with triple stage fragmentation to enhance sensitivity and selectivity","volume":"13","author":"Shi","year":"2021","journal-title":"Anal. Methods"},{"key":"10.1016\/j.jpba.2022.115017_bib20","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jpha.2012.09.001","article-title":"Liquid chromatography tandem mass spectrometry method for the estimation of lamotrigine in human plasma: application to a pharmacokinetic study","volume":"3","author":"Ghatol","year":"2013","journal-title":"J. Pharm. Anal."},{"key":"10.1016\/j.jpba.2022.115017_bib21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1097\/01.ftd.0000245779.64080.30","article-title":"Determination of lamotrigine and its metabolites in human plasma by liquid chromatography-mass spectrometry","volume":"28","author":"Beck","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2022.115017_bib22","unstructured":"F.D.A. Bioanalytical Method Validation Guidance for Industry. Available at: https:\/\/www.fda.gov\/ucm\/groups\/fdagov-public\/@fdagov-drugs-gen\/documents\/document\/ucm070107.pdf., 2018."},{"key":"10.1016\/j.jpba.2022.115017_bib23","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1002\/jssc.200700110","article-title":"Rapid HPLC analysis of the antiepileptic lamotrigine and its metabolites in human plasma","volume":"30","author":"Saracino","year":"2007","journal-title":"J. Sep. Sci."},{"key":"10.1016\/j.jpba.2022.115017_bib24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0378-4347(97)00360-5","article-title":"Simultaneous determination of lamotrigine and its glucuronide and methylated metabolites in human plasma by automated sequential trace enrichment of dialysates and gradient high-performance liquid chromatography","volume":"702","author":"Cooper","year":"1997","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/j.jpba.2022.115017_bib25","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.2174\/1573411016666200108143049","article-title":"Simultaneous determination of lamotrigine, topiramate, oxcarbazepine, and 10,11-dihydro-10-hydroxycarbazepine in human blood plasma by UHPLC-MS\/MS","volume":"16","author":"Zhao","year":"2020","journal-title":"Curr. Anal. Chem."},{"key":"10.1016\/j.jpba.2022.115017_bib26","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/00007691-200112000-00021","article-title":"Potential lack of specificity using electrospray tandem-mass spectrometry for the analysis of mycophenolic acid in serum","volume":"23","author":"Vogeser","year":"2001","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2022.115017_bib27","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jpba.2022.115017_bib28","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: A 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2022.115017_bib29","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1528-1167.2007.01471.x","article-title":"Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy","volume":"49","author":"Ohman","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpba.2022.115017_bib30","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/elps.200410208","article-title":"Analysis of lamotrigine and its metabolites in human plasma and urine by micellar electrokinetic capillary chromatography","volume":"26","author":"Pucci","year":"2005","journal-title":"Electrophoresis"},{"key":"10.1016\/j.jpba.2022.115017_bib31","article-title":"Fast liquid chromatography-tandem mass spectrometry method for simultaneous determination of eight antiepileptic drugs and an active metabolite in human plasma using polarity switching and timed selected reaction monitoring","volume":"176","author":"Liu","year":"2019","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2022.115017_bib32","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0021-9673(01)88448-X","article-title":"Use of thermospray liquid chromatography-mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, Lamotrigine","volume":"554","author":"Doig","year":"1991","journal-title":"J. Chromatogr."},{"key":"10.1016\/j.jpba.2022.115017_bib33","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1111\/j.1528-1167.2011.03217.x","article-title":"The effect of age and comedication on lamotrigine clearance, tolerability, and efficacy","volume":"52","author":"Arif","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.jpba.2022.115017_bib34","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40262-017-0614-5","article-title":"Effect of age-related factors on the pharmacokinetics of lamotrigine and potential implications for maintenance dose optimisation in future clinical trials","volume":"57","author":"van Dijkman","year":"2018","journal-title":"Clin. Pharmacokinet"},{"key":"10.1016\/j.jpba.2022.115017_bib35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2125.1997.00594.x","article-title":"Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data","volume":"43","author":"Hussein","year":"1997","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.jpba.2022.115017_bib36","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1016\/j.xphs.2020.05.030","article-title":"Dosing recommendations based on population pharmacokinetics of lamotrigine in mexican adult patients with epilepsy","volume":"109","author":"Chavez-Castillo","year":"2020","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2022.115017_bib37","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00228-018-2414-8","article-title":"Population pharmacokinetics of lamotrigine co-administered with valproic acid in Chinese epileptic children using nonlinear mixed effects modeling","volume":"74","author":"Xu","year":"2018","journal-title":"Eur. J. Clin Pharmacol."},{"key":"10.1016\/j.jpba.2022.115017_bib38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/bcp.12984","article-title":"Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: influence of polymorphism of UDP-glucuronosyltransferases and drug transporters","volume":"82","author":"Milosheska","year":"2016","journal-title":"Br. J. Clin. Pharm."},{"key":"10.1016\/j.jpba.2022.115017_bib39","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/FTD.0000000000000433","article-title":"Lamotrigine drug interactions in combination therapy and the influence of therapeutic drug monitoring on clinical outcomes of adult patients","volume":"39","author":"Grundmann","year":"2017","journal-title":"Ther. Drug Monit."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522004381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708522004381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:24:32Z","timestamp":1760001872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708522004381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":39,"alternative-id":["S0731708522004381"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2022.115017","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous determination of plasma lamotrigine, lamotrigine N2-glucuronide and lamotrigine N2-oxide by UHPLC-MS\/MS in epileptic patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2022.115017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115017"}}